Verrica Pharmaceuticals宣布对其与Torii Pharmaceuticals的现有合作和许可协议进行第二次修正，以启动Verrica的Ycanth治疗常见疣的全球初步第三阶段试验

2025-07-01 19:06

Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule.
Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025.
Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget.
Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for this multi-billion dollar addressable market.
Company expects to dose first patient in the Phase 3 trial in the United States in the fourth quarter of 2025.
Verrica to maintain ownership of global rights to YCANTH for all indications in all territories outside of Japan